These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 21241234

  • 21. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G, Ruilope LM.
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [Abstract] [Full Text] [Related]

  • 22. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
    Vijayaraghavan K, Deedwania P.
    Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
    Li SM, He WB, Chen J, Cai QQ, Huang FF, Zhang K, Wang JF, Liu X, Huang H.
    Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
    [Abstract] [Full Text] [Related]

  • 25. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
    Rutkowski B, Tylicki L.
    J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS.
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G, Perico N, Macia M, Ruggenenti P.
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [Abstract] [Full Text] [Related]

  • 29. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 30. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [Abstract] [Full Text] [Related]

  • 31. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R, Sellers F.
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [Abstract] [Full Text] [Related]

  • 34. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 35. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH, Fu P.
    Chin Med J (Engl); 2016 Jan 05; 129(1):81-7. PubMed ID: 26712437
    [Abstract] [Full Text] [Related]

  • 36. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K, Smith H, Biederman J.
    Prim Care; 2014 Dec 05; 41(4):765-78. PubMed ID: 25439533
    [Abstract] [Full Text] [Related]

  • 37. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug 05; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

  • 38. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Aug 05; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 39. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials.
    Stojiljkovic L, Behnia R.
    Curr Pharm Des; 2007 Aug 05; 13(13):1335-45. PubMed ID: 17506719
    [Abstract] [Full Text] [Related]

  • 40. Disputes in the Treatment of Diabetic Nephropathy: The Dual Blockade of Renin-Angiotensin System.
    Grolla E, Bonanni L, Cutolo A, Presotto F, Dalla Vestra M.
    Exp Clin Endocrinol Diabetes; 2016 Jun 05; 124(6):361-6. PubMed ID: 27219891
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.